Peter J Sciavolino, PhD | Authors


BRAF Testing Important for Clinical Decision-Making in Metastatic Melanoma

January 05, 2016

With the continuously expanding landscape of treatment options for advanced and/or metastatic melanoma, it is becoming increasingly important to understand the patient-specific oncogenic drivers as a means of selecting treatments.

The Next Wave in Immunotherapy: Combinations

August 19, 2014

Advances in our understanding of critical immunomodulatory checkpoints, such as the cytotoxic T-lymphocyte antigen 4 (CTLA-4), have led to some recent notable successes in the immunotherapy of cancer.